CA2730534C - Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe - Google Patents

Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe Download PDF

Info

Publication number
CA2730534C
CA2730534C CA2730534A CA2730534A CA2730534C CA 2730534 C CA2730534 C CA 2730534C CA 2730534 A CA2730534 A CA 2730534A CA 2730534 A CA2730534 A CA 2730534A CA 2730534 C CA2730534 C CA 2730534C
Authority
CA
Canada
Prior art keywords
formulation
diethylene glycol
trihydroxystilbene
resveratrol
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2730534A
Other languages
English (en)
French (fr)
Other versions
CA2730534A1 (fr
Inventor
Laurent Pechere
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YVERY
Original Assignee
YVERY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YVERY filed Critical YVERY
Publication of CA2730534A1 publication Critical patent/CA2730534A1/fr
Application granted granted Critical
Publication of CA2730534C publication Critical patent/CA2730534C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2730534A 2008-07-18 2009-07-16 Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe Expired - Fee Related CA2730534C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0804098 2008-07-18
FR0804098A FR2933871B1 (fr) 2008-07-18 2008-07-18 Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
PCT/FR2009/000868 WO2010007252A2 (fr) 2008-07-18 2009-07-16 Formulation destinée à améliorer la biodisponibilité d'une molécule hydrophobe

Publications (2)

Publication Number Publication Date
CA2730534A1 CA2730534A1 (fr) 2010-01-21
CA2730534C true CA2730534C (fr) 2017-10-24

Family

ID=40377450

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2730534A Expired - Fee Related CA2730534C (fr) 2008-07-18 2009-07-16 Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe

Country Status (7)

Country Link
US (1) US20110184072A1 (enExample)
EP (1) EP2315583B1 (enExample)
JP (1) JP2011528336A (enExample)
CA (1) CA2730534C (enExample)
ES (1) ES2686596T3 (enExample)
FR (1) FR2933871B1 (enExample)
WO (1) WO2010007252A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CA3023725C (en) 2009-10-22 2021-09-14 Vizuri Health Sciences Llc Methods of producing hydrated flavonoids and use thereof in the preparation of topical compositions
CA2792993A1 (fr) * 2010-01-21 2011-07-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Composition particuliere pour son application comme medicament
EP2629763B1 (en) * 2010-10-22 2017-12-06 Vizuri Health Sciences LLC Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CN115236250A (zh) * 2022-06-27 2022-10-25 武汉轻工大学 一种乳液对白藜芦醇的生物利用度改善效果的检测方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329503A1 (de) * 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
IT1286778B1 (it) * 1996-11-20 1998-07-17 Alfa Wassermann Spa Capsule contenenti diclofenac o suoi sali in soluzione
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6414037B1 (en) * 1998-01-09 2002-07-02 Pharmascience Pharmaceutical formulations of resveratrol and methods of use thereof
IL138616A0 (en) * 2000-09-21 2001-10-31 J P M E D Ltd Oil in glycerin emulsion
US6890547B1 (en) * 1999-07-16 2005-05-10 Amato Pharmaceutical Products, Ltd. Glycyrrhizin preparations for transmucosal absorption
PE20010540A1 (es) * 1999-07-30 2001-05-15 Procter & Gamble Composicion de fitoalexinas estilbenicas util para la profilaxis y tratamiento de sintomas asociados con el resfriado y enfermedades similares a la influenza
FR2820975B1 (fr) * 2001-02-21 2004-03-12 Oreal Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene
JP2003231684A (ja) * 2002-02-06 2003-08-19 Ichimaru Pharcos Co Ltd コレステロール代謝改善剤
WO2004071490A1 (en) * 2003-02-12 2004-08-26 R & P Korea Co., Ltd. Solvent system of hardly soluble drug with improved elution rate
ES2344920T3 (es) * 2006-03-28 2010-09-09 Epitech Group S.R.L. Composicion farmaceutica para el tratamiento de patologias provocadas por la respuesta general del sistema inmutario.
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
JP2007314472A (ja) * 2006-05-26 2007-12-06 Oriza Yuka Kk 体臭抑制剤
JP2008088123A (ja) * 2006-10-03 2008-04-17 Oriza Yuka Kk 美肌用組成物
JP2008239576A (ja) * 2007-03-28 2008-10-09 Koei Kogyo Kk ブドウの芽及び蔓から抽出したレスベラトロール類を含有する組成物
JP2008290982A (ja) * 2007-05-25 2008-12-04 Oriza Yuka Kk 水溶性スチルベン粉末製剤

Also Published As

Publication number Publication date
EP2315583A2 (fr) 2011-05-04
US20110184072A1 (en) 2011-07-28
WO2010007252A2 (fr) 2010-01-21
CA2730534A1 (fr) 2010-01-21
JP2011528336A (ja) 2011-11-17
EP2315583B1 (fr) 2018-05-09
ES2686596T3 (es) 2018-10-18
WO2010007252A3 (fr) 2010-12-16
FR2933871A1 (fr) 2010-01-22
FR2933871B1 (fr) 2012-12-14

Similar Documents

Publication Publication Date Title
EP0724877B1 (fr) Association de fénofibrate et de vitamine E, utilisation en thérapeutique
BE1009198A5 (fr) Compositions pharmaceutiques nouvelles contenant du propofol.
EP0862423B1 (fr) Composition pharmaceutique pour administration par voie orale
CA2680433C (fr) Nouvelle composition a base d'oxime de cholest-4-en-3-one
CA2730534C (fr) Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
EP3735230A1 (en) Modified release composition comprising a cannabinoid
FR2737121A1 (fr) Nouvelles formulations galeniques du fenofibrate et leurs applications
EP1458413B1 (fr) Compositions pharmaceutiques a base de derives d azetidine
FR2692783A1 (fr) Compositions à base de fractions insaponifiables d'huiles de germe de blé et de sésame, et leurs utilisations notamment en cosmétologie et en qualité de complément alimentaire.
EP0927026A1 (fr) Compositions pharmaceutiques comprenant de l'amisulpride et leurs applications therapeutiques
BE1011077A3 (fr) Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes.
WO2011089168A2 (fr) Composition particuliere pour son application comme medicament
EP1691808A1 (fr) Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide
EP0775488B1 (fr) Composition pharmaceutique stable à base d'acide acétylsalicyclique et de tocophérol
EP1835906A1 (fr) Formulations injectables ou administrables par voie orale de derives d'azetidine
EP2600845A2 (fr) Composition pharmaceutique contenant un extrait de serenoa repens
WO2001076551A1 (fr) Composition cosmetique ou pharmaceutique contenant une lactone sesquiterpenique
FR2855412A1 (fr) Composition a liberation prolongee de magnesium, et son application dans le domaine therapeutique, cosmetique et nutritionnel
BE1026269B1 (fr) Formulation à propriétés anti-inflammatoires
GB2633109A (en) Method of forming a liposome comprising a derivative of curcumin
FR3159901A1 (fr) Assemblage moléculaire pour l’encapsulation de molécules hydrophobes, ledit assemblage ayant les molécules hydrophobes encapsulées, procédés de fabrication correspondants et utilisations
WO2009095560A1 (fr) Compositions pharmaceutiques a base de derives d´azetidine

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140620

MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831